Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Asparaginase (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Idarubicin (Primary) ; Methotrexate (Primary) ; Folinic acid
- Indications Blastic plasmacytoid dendritic cell neoplasm
- Focus Therapeutic Use
- Acronyms LpDessai
- 18 Mar 2019 Status changed from not yet recruiting to recruiting.
- 28 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 10 Dec 2018 Planned initiation date changed from 1 Sep 2018 to 1 Jan 2019.